Multiscale technologies for treatment of ischemic cardiomyopathy
Source abstract
Abstract
The adult mammalian heart possesses only limited capacity for innate regeneration and the response to severe injury is dominated by the formation of scar tissue. Current therapy to replace damaged cardiac tissue is limited to cardiac transplantation and thus many patients suffer progressive decay in the heart's pumping capacity to the point of heart failure. Nanostructured systems have the potential to revolutionize both preventive and therapeutic approaches for treating cardiovascular disease. Here, we outline recent advancements in nanotechnology that could be exploited to overcome the major obstacles in the prevention of and therapy for heart disease. We also discuss emerging trends in nanotechnology affecting the cardiovascular field that may offer new hope for patients suffering massive heart attacks.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Tissue Engineering and Regenerative Medicine · Neuroscience and Neural Engineering · Electrospun Nanofibers in Biomedical Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Bui, A. L., Horwich, T. B. & Fonarow, G. C. Epidemiology and risk profile of heart failure. Nat. Rev. Cardiol. 8, 30–41 (2011).10.1038/nrcardio.2010.165 ↗
2. Johnson, N. B. et al. CDC National Health Report: leading causes of morbidity and mortality and associated behavioral risk and protective factors—United States, 2005–2013. MMWR Surveill. Summ. 63, 3–27 (2014).
3. Thygesen, K., Alpert, J. S. & White, H. D. Universal definition of myocardial infarction. J. Am. Coll. Cardiol. 50, 2173–2195 (2007).10.1016/j.jacc.2007.09.011 ↗
4. Cassar, A., Holmes, D. R. Jr., Rihal, C. S. & Gersh, B. J. Chronic coronary artery disease: diagnosis and management. Mayo Clin. Proc. 84, 1130–1146 (2009).10.4065/mcp.2009.0391 ↗
5. White, H. D. & Chew, D. P. Acute myocardial infarction. Lancet 372, 570–584 (2008).10.1016/S0140-6736(08)61237-4 ↗
6. Senyo, S. E. et al. Mammalian heart renewal by pre-existing cardiomyocytes. Nature 493, 433–436 (2013).10.1038/nature11682 ↗
7. Ziaeian, B. & Fonarow, G. C. Epidemiology and aetiology of heart failure. Nat. Rev. Cardiol. 13, 368–378 (2016).10.1038/nrcardio.2016.25 ↗
8. Dunlay, S. M. & Roger, V. L. Understanding the epidemic of heart failure: past, present, and future. Curr. Heart Fail. Rep. 11, 404–415 (2014).10.1007/s11897-014-0220-x ↗
9. Wijns, W. et al. Guidelines on myocardial revascularization. Eur. Heart J. 31, 2501–2555 (2010).10.1093/eurheartj/ehq172 ↗
10. Libby, P., Ridker, P. M. & Maseri, A. Inflammation and atherosclerosis. Circulation 105, 1135–1143 (2002).10.1161/hc0902.104353 ↗
11. Nabel, E. G. & Braunwald, E. A tale of coronary artery disease and myocardial infarction. N. Engl. J. Med. 366, 54–63 (2012).10.1056/NEJMra1112570 ↗
12. Libby, P., Ridker, P. M. & Hansson, G. K. Progress and challenges in translating the biology of atherosclerosis. Nature 473, 317–325 (2011).10.1038/nature10146 ↗
13. Begum, M. & Sharma, H. Scope of nanomedicine against coronary artery disease: a review. Eur. J. Pharm. Med. Res. 3, 635–641 (2016).
14. Mahmoudi, M. et al. Protein−nanoparticle interactions: opportunities and challenges. Chem. Rev. 111, 5610–5637 (2011).10.1021/cr100440g ↗
15. Nahrendorf, M. et al. Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis. Circulation 117, 379–387 (2008).10.1161/CIRCULATIONAHA.107.741181 ↗
16. Mahmoudi, M., Serpooshan, V. & Laurent, S. Engineered nanoparticles for biomolecular imaging. Nanoscale 3, 3007–3026 (2011).10.1039/c1nr10326a ↗
17. Sanz, J. & Fayad, Z. A. Imaging of atherosclerotic cardiovascular disease. Nature 451, 953–957 (2008).10.1038/nature06803 ↗
18. Zanganeh, S. et al. Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues. Nat. Nanotech. 11, 986–994 (2016).10.1038/nnano.2016.168 ↗
19. Lobatto, M. E., Fuster, V., Fayad, Z. A. & Mulder, W. J. Perspectives and opportunities for nanomedicine in the management of atherosclerosis. Nat. Rev. Drug Discov. 10, 835–852 (2011).10.1038/nrd3578 ↗
20. Korin, N. et al. Shear-activated nanotherapeutics for drug targeting to obstructed blood vessels. Science 337, 738–742 (2012).10.1126/science.1217815 ↗
21. Fredman, G. et al. Targeted nanoparticles containing the proresolving peptide Ac2–26 protect against advanced atherosclerosis in hypercholesterolemic mice. Sci. Transl. Med. 7, 275ra220 (2015).
22. Kamaly, N. et al. Targeted interleukin-10 nanotherapeutics developed with a microfluidic chip enhance resolution of inflammation in advanced atherosclerosis. ACS Nano 10, 5280–5292 (2016).10.1021/acsnano.6b01114 ↗
23. Kamaly, N. et al. Development and in vivo efficacy of targeted polymeric inflammation-resolving nanoparticles. Proc. Natl Acad. Sci. USA 110, 6506–6511 (2013).10.1073/pnas.1303377110 ↗
24. Kamaly, N., He, J. C., Ausiello, D. A. & Farokhzad, O. C. Nanomedicines for renal disease: current status and future applications. Nat. Rev. Nephrol. 12, 738–753 (2016).10.1038/nrneph.2016.156 ↗
25. Duivenvoorden, R. et al. A statin-loaded reconstituted high-density lipoprotein nanoparticle inhibits atherosclerotic plaque inflammation. Nat. Commun. 5, 3531 (2014).10.1038/ncomms4531 ↗
26. Chan, J. M. et al. Spatiotemporal controlled delivery of nanoparticles to injured vasculature. Proc. Natl Acad. Sci. USA 107, 2213–2218 (2010).10.1073/pnas.0914585107 ↗
27. Chnari, E., Nikitczuk, J. S., Wang, J., Uhrich, K. E. & Moghe, P. V. Engineered polymeric nanoparticles for receptor-targeted blockage of oxidized low density lipoprotein uptake and atherogenesis in macrophages. Biomacromolecules 7, 1796–1805 (2006).10.1021/bm0600872 ↗
28. Lewis, D. R. et al. Sugar-based amphiphilic nanoparticles arrest atherosclerosis in vivo. Proc. Natl Acad. Sci. USA 112, 2693–2698 (2015).10.1073/pnas.1424594112 ↗
29. Tomasini, M. D., Zablocki, K., Petersen, L. K., Moghe, P. V. & Tomassone, M. S. Coarse grained molecular dynamics of engineered macromolecules for the inhibition of oxidized low-density lipoprotein uptake by macrophage scavenger receptors. Biomacromolecules 14, 2499–2509 (2013).10.1021/bm301764x ↗
30. Monopoli, M. P., Åberg, C., Salvati, A. & Dawson, K. A. Biomolecular coronas provide the biological identity of nanosized materials. Nat. Nanotech. 7, 779–786 (2012).10.1038/nnano.2012.207 ↗
31. Mahmoudi, M. Protein corona: The golden gate to clinical applications of nanoparticles. Int. J. Biochem. Cell Biol. 75, 141–142 (2016).10.1016/j.biocel.2016.03.016 ↗
32. Caracciolo, G., Farokhzad, O. C. & Mahmoudi, M. Biological identity of nanoparticles in vivo: clinical implications of the protein corona. Trends Biotechnol. 35, 257–264 (2017).10.1016/j.tibtech.2016.08.011 ↗
33. Salvati, A. et al. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat. Nanotech. 7, 779–786 (2012).10.1038/nnano.2012.207 ↗
34. Mirshafiee, V., Mahmoudi, M., Lou, K., Cheng, J. & Kraft, M. L. Protein corona significantly reduces active targeting yield. Chem. Commun. 49, 2557–2559 (2013).10.1039/c3cc37307j ↗
35. Behzadi, S. et al. Protein corona change the drug release profile of nanocarriers: the “overlooked” factor at the nanobio interface. Colloids Surf. B 123, 143–149 (2014).10.1016/j.colsurfb.2014.09.009 ↗
36. Moyano, D. F. et al. Fabrication of corona-free nanoparticles with tunable hydrophobicity. ACS Nano 8, 6748–6755 (2014).10.1021/nn5006478 ↗
37. Mirshafiee, V., Kim, R., Park, S., Mahmoudi, M. & Kraft, M. L. Impact of protein pre-coating on the protein corona composition and nanoparticle cellular uptake. Biomaterials 75, 295–304 (2016).10.1016/j.biomaterials.2015.10.019 ↗
38. Deng, Z. J., Liang, M., Monteiro, M., Toth, I. & Minchin, R. F. Nanoparticle-induced unfolding of fibrinogen promotes Mac-1 receptor activation and inflammation. Nat. Nanotech. 6, 39–44 (2011).10.1038/nnano.2010.250 ↗
39. Behfar, A., Crespo-Diaz, R., Terzic, A. & Gersh, B. J. Cell therapy for cardiac repair—lessons from clinical trials. Nat. Rev. Cardiol. 11, 232–246 (2014).10.1038/nrcardio.2014.9 ↗
40. Nguyen, P. K., Rhee, J. W. & Wu, J. C. Adult stem cell therapy and heart failure, 2000 to 2016: a systematic review. JAMA Cardiol. 1, 831–841 (2016).10.1001/jamacardio.2016.2225 ↗
41. Burridge, P. W., Keller, G., Gold, J. D. & Wu, J. C. Production of de novo cardiomyocytes: human pluripotent stem cell differentiation and direct reprogramming. Cell Stem Cell 10, 16–28 (2012).10.1016/j.stem.2011.12.013 ↗
42. Ranganath, S. H., Levy, O., Inamdar, M. S. & Karp, J. M. Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease. Cell Stem Cell 10, 244–258 (2012).10.1016/j.stem.2012.02.005 ↗
43. Nguyen, P. K., Neofytou, E., Rhee, J.-W. & Wu, J. C. Potential strategies to address the major clinical barriers facing stem cell regenerative therapy for cardiovascular disease: a review. JAMA Cardiol. 1, 953–962 (2016).10.1001/jamacardio.2016.2750 ↗
44. Mahmoudi, M. et al. Novel MRI contrast agent from magnetotactic bacteria enables in vivo tracking of iPSC-derived cardiomyocytes. Sci. Rep. 6, 26960 (2016).10.1038/srep26960 ↗
45. Chong, J. J. et al. Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts. Nature 510, 273–277 (2014).10.1038/nature13233 ↗
46. Riegler, J. et al. Comparison of magnetic resonance imaging and serum biomarkers for detection of human pluripotent stem cell-derived teratomas. Stem Cell Rep. 6, 176–187 (2016).10.1016/j.stemcr.2015.12.008 ↗
47. Burridge, P. W. et al. Chemically defined generation of human cardiomyocytes. Nat. Methods 11, 855–860 (2014).10.1038/nmeth.2999 ↗
48. Cheng, K. et al. Magnetic antibody-linked nanomatchmakers for therapeutic cell targeting. Nat. Commun. 5, 4880 (2014).10.1038/ncomms5880 ↗
49. Shiba, Y. et al. Human ES-cell-derived cardiomyocytes electrically couple and suppress arrhythmias in injured hearts. Nature 489, 322–325 (2012).10.1038/nature11317 ↗
50. Kawamura, M. et al. Feasibility, safety, and therapeutic efficacy of human induced pluripotent stem cell-derived cardiomyocyte sheets in a porcine ischemic cardiomyopathy model. Circulation 126, S29–S37 (2012).10.1161/CIRCULATIONAHA.111.084343 ↗
51. Laflamme, M. A. & Murry, C. E. Heart regeneration. Nature 473, 326–335 (2011).10.1038/nature10147 ↗
52. Mirotsou, M. et al. Secreted frizzled related protein 2 (Sfrp2) is the key Akt-mesenchymal stem cell-released paracrine factor mediating myocardial survival and repair. Proc. Natl Acad. Sci. USA 104, 1643–1648 (2007).10.1073/pnas.0610024104 ↗
53. Han, J. et al. Iron oxide nanoparticle-mediated development of cellular gap junction crosstalk to improve mesenchymal stem cells' therapeutic efficacy for myocardial infarction. ACS Nano 9, 2805–2819 (2015).10.1021/nn506732n ↗
54. Vandergriff, A. C. et al. Magnetic targeting of cardiosphere-derived stem cells with ferumoxytol nanoparticles for treating rats with myocardial infarction. Biomaterials 35, 8528–8539 (2014).10.1016/j.biomaterials.2014.06.031 ↗
55. Xu, C. et al. Tracking mesenchymal stem cells with iron oxide nanoparticle loaded poly (lactide-co-glycolide) microparticles. Nano Lett. 12, 4131–4139 (2012).10.1021/nl301658q ↗
56. Yang, X. Magnetic Resonance Imaging of Stem Cell Applications (Nova Science, 2015).
57. Mahmoudi, M., Bertrand, N., Zope, H. & Farokhzad, O. Emerging understanding of the nano-bio interface in nanomedicin. Nano Today 11, 817–832 (2016).10.1016/j.nantod.2016.10.005 ↗
58. Chen, I. Y. et al. Comparison of optical bioluminescence reporter gene and superparamagnetic iron oxide MR contrast agent as cell markers for noninvasive imaging of cardiac cell transplantation. Mol. Imaging Biol. 11, 178–187 (2009).10.1007/s11307-008-0182-z ↗
59. Terrovitis, J. et al. Magnetic resonance imaging overestimates ferumoxide-labeled stem cell survival after transplantation in the heart. Circulation 117, 1555–1562 (2008).10.1161/CIRCULATIONAHA.107.732073 ↗
60. Nguyen, P. K., Riegler, J. & Wu, J. C. Stem cell imaging: from bench to bedside. Cell Stem Cell 14, 431–444 (2014).10.1016/j.stem.2014.03.009 ↗
61. Takahama, H. et al. Liposomal amiodarone augments anti-arrhythmic effects and reduces hemodynamic adverse effects in an ischemia/reperfusion rat model. Cardiovasc. Drugs Ther. 27, 125–132 (2013).10.1007/s10557-012-6437-6 ↗
62. Ewer, M. S. & Ewer, S. M. Cardiotoxicity of anticancer treatments: what the cardiologist needs to know. Nat. Rev. Cardiol. 7, 564–575 (2010).10.1038/nrcardio.2010.121 ↗
63. Burridge, P. et al. Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity. Nat. Med. 22, 547–556 (2016).10.1038/nm.4087 ↗
64. Louch, W. E., Sheehan, K. A. & Wolska, B. M. Methods in cardiomyocyte isolation, culture, and gene transfer. J. Mol. Cell. Cardiol. 51, 288–298 (2011).10.1016/j.yjmcc.2011.06.012 ↗
65. Yang, X., Pabon, L. & Murry, C. E. Engineering adolescence maturation of human pluripotent stem cell–derived cardiomyocytes. Circ. Res. 114, 511–523 (2014).10.1161/CIRCRESAHA.114.300558 ↗
66. Kattman, S. J. et al. Stage-specific optimization of activin/nodal and BMP signaling promotes cardiac differentiation of mouse and human pluripotent stem cell lines. Cell Stem Cell 8, 228–240 (2011).10.1016/j.stem.2010.12.008 ↗
67. Sharma, A. et al. High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells. Sci. Transl. Med. 9, eaaf2584 (2017).10.1126/scitranslmed.aaf2584 ↗
68. Wei, K. et al. Epicardial FSTL1 reconstitution regenerates the adult mammalian heart. Nature 525, 479–485 (2015).10.1038/nature15372 ↗
69. Ribeiro, A. J. et al. Contractility of single cardiomyocytes differentiated from pluripotent stem cells depends on physiological shape and substrate stiffness. Proc. Natl Acad. Sci. USA 112, 12705–12710 (2015).10.1073/pnas.1508073112 ↗
70. Sayed, N., Liu, C. & Wu, J. C. Translation of human-induced pluripotent stem cells: from clinical trial in a dish to precision medicine. J. Am. Coll. Cardiol. 67, 2161–2176 (2016).10.1016/j.jacc.2016.01.083 ↗
71. O'Cearbhaill, E. D., Ng, K. S. & Karp, J. Emerging medical devices for minimally invasive cell therapy. Mayo Clin. Proc. 89, 259–273 (2014).10.1016/j.mayocp.2013.10.020 ↗
72. Wang, G. et al. Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies. Nat. Med. 20, 616–623 (2014).10.1038/nm.3545 ↗
73. Yang, H. S. et al. Electroconductive nanopatterned substrates for enhanced myogenic differentiation and maturation. Adv. Healthcare Mater. 5, 137–145 (2016).10.1002/adhm.201500003 ↗
74. Wang, P.-Y., Yu, J., Lin, J.-H. & Tsai, W.-B. Modulation of alignment, elongation and contraction of cardiomyocytes through a combination of nanotopography and rigidity of substrates. Acta Biomater. 7, 3285–3293 (2011).10.1016/j.actbio.2011.05.021 ↗
75. Macadangdang, J. et al. Nanopatterned human iPSC-based model of a dystrophin-null cardiomyopathic phenotype. Cell. Mol. Bioeng. 8, 320–332 (2015).10.1007/s12195-015-0413-8 ↗
76. Carson, D. et al. Nanotopography-induced structural anisotropy and sarcomere development in human cardiomyocytes derived from induced pluripotent stem cells. ACS Appl. Mater. Interfaces 8, 21923–21932 (2016).10.1021/acsami.5b11671 ↗
77. French, A. et al. Enabling consistency in pluripotent stem cell-derived products for research and development and clinical applications through material standards. Stem Cells Transl. Med. 4, 217–223 (2015).10.5966/sctm.2014-0233 ↗
78. Laflamme, M. A. et al. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat. Biotechnol. 25, 1015–1024 (2007).10.1038/nbt1327 ↗
79. Mashinchian, O. et al. Regulation of stem cell fate by nanomaterial substrates. Nanomedicine 10, 829–847 (2015).10.2217/nnm.14.225 ↗
80. Mahmoudi, M. et al. Cell-imprinted substrates direct the fate of stem cells. ACS Nano 7, 8379–8384 (2013).10.1021/nn403844q ↗
81. Mashinchian, O. et al. Cell-imprinted substrates act as an artificial niche for skin regeneration. ACS Appl. Mater. Interfaces 6, 13280–13292 (2014).10.1021/am503045b ↗
82. Bonakdar, S. et al. Cell-imprinted substrates modulate differentiation, redifferentiation, and transdifferentiation. ACS Appl. Mater. Interfaces 8, 13777–13784 (2016).10.1021/acsami.6b03302 ↗
83. Wekerle, T. & Grinyó, J. M. Belatacept: from rational design to clinical application. Transpl. Int. 25, 139–150 (2012).10.1111/j.1432-2277.2011.01386.x ↗
84. Sharma, P. & Allison, J. P. The future of immune checkpoint therapy. Science 348, 56–61 (2015).10.1126/science.aaa8172 ↗
85. Rong, Z. et al. An effective approach to prevent immune rejection of human ESC-derived allografts. Cell Stem Cell 14, 121–130 (2014).10.1016/j.stem.2013.11.014 ↗
86. Uyttenhove, C. et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2, 3-dioxygenase. Nat. Med. 9, 1269–1274 (2003).10.1038/nm934 ↗
87. Evans, C. W., Iyer, K. S. & Hool, L. C. The potential for nanotechnology to improve delivery of therapy to the acute ischemic heart. Nanomedicine 11, 817–832 (2016).10.2217/nnm.16.7 ↗
88. Heusch, G. et al. Cardiovascular remodelling in coronary artery disease and heart failure. Lancet 383, 1933–1943 (2014).10.1016/S0140-6736(14)60107-0 ↗
89. Dvir, T. et al. Nanoparticles targeting the infarcted heart. Nano Lett. 11, 4411–4414 (2011).10.1021/nl2025882 ↗
90. Matsumura, Y. & Maeda, H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46, 6387–6392 (1986).
91. Gerlowski, L. E. & Jain, R. K. Microvascular permeability of normal and neoplastic tissues. Microvasc. Res. 31, 288–305 (1986).10.1016/0026-2862(86)90018-X ↗
92. Bertrand, N., Wu, J., Xu, X., Kamaly, N. & Farokhzad, O. C. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv. Drug Delivery Rev. 66, 2–25 (2014).10.1016/j.addr.2013.11.009 ↗
93. Maeda, H. Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity. Adv. Drug Delivery Rev. 91, 3–6 (2015).10.1016/j.addr.2015.01.002 ↗
94. Shi, J., Kantoff, P. W., Wooster, R. & Farokhzad, O. C. Cancer nanomedicine: progress, challenges and opportunities. Nat. Rev. Cancer 17, 20–37 (2017).10.1038/nrc.2016.108 ↗
95. Hardy, N. et al. Nanoparticle-mediated dual delivery of an antioxidant and a peptide against the L-Type Ca2+ channel enables simultaneous reduction of cardiac ischemia-reperfusion injury. ACS Nano 9, 279–289 (2014).10.1021/nn5061404 ↗
96. Leuschner, F. et al. Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat. Biotechnol. 29, 1005–1010 (2011).10.1038/nbt.1989 ↗
97. Force, T., Krause, D. S. & Van Etten, R. A. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat. Rev. Cancer 7, 332–344 (2007).10.1038/nrc2106 ↗
98. Yeh, E. T. H. et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 109, 3122–3131 (2004).10.1161/01.CIR.0000133187.74800.B9 ↗
99. Nasr, M., Nafee, N., Saad, H. & Kazem, A. Improved antitumor activity and reduced cardiotoxicity of epirubicin using hepatocyte-targeted nanoparticles combined with tocotrienols against hepatocellular carcinoma in mice. Eur. J. Pharm. Biopharm. 88, 216–225 (2014).10.1016/j.ejpb.2014.04.016 ↗
100. Setyawati, M. et al. Titanium dioxide nanomaterials cause endothelial cell leakiness by disrupting the homophilic interaction of VE–cadherin. Nat. Commun. 4, 1673 (2013).10.1038/ncomms2655 ↗